Lazard Asset Management LLC Acquires 65,420 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Lazard Asset Management LLC raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 68.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 161,516 shares of the biotechnology company's stock after buying an additional 65,420 shares during the period. Lazard Asset Management LLC owned about 0.08% of BioCryst Pharmaceuticals worth $1,214,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of BCRX. Vanguard Group Inc. raised its stake in BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after buying an additional 1,583,826 shares during the period. Eversept Partners LP raised its stake in BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after buying an additional 1,444,907 shares during the period. Hillsdale Investment Management Inc. raised its stake in BioCryst Pharmaceuticals by 65,213.3% in the fourth quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock valued at $4,077,000 after buying an additional 541,270 shares during the period. Balyasny Asset Management L.P. bought a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $3,983,000. Finally, Norges Bank bought a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $3,947,000. Institutional investors own 85.88% of the company's stock.

Wall Street Analysts Forecast Growth

BCRX has been the topic of several research analyst reports. Barclays upped their price objective on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. Wall Street Zen raised BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday. Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price on the stock. JPMorgan Chase & Co. upped their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Stock Up 1.9%

Shares of BioCryst Pharmaceuticals stock traded up $0.20 on Friday, hitting $10.59. The stock had a trading volume of 3,608,168 shares, compared to its average volume of 3,026,377. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -17.36 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a twelve month low of $5.92 and a twelve month high of $11.11. The business's 50 day moving average is $8.38 and its two-hundred day moving average is $8.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. BioCryst Pharmaceuticals's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.28 earnings per share. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.